ASPIC

Authors and Affiliations:
Rita F. Oliveira ^1,2, Ana I. Oliveira ¹, Agostinho Cruz ¹, Oscar Ribeiro ², Vera Afreixo ³ and Francisco Pimentel ⁴

¹ REQUIMTE/LAQV, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal

Authors and Affiliations:

Diana Luísa Almeida-Nunes ^1,2,3, João P. N. Silva ⁴, Mariana Nunes ^3,5, Patrícia M. A. Silva ^1,4,6, Ricardo Silvestre ^7,8, Ricardo Jorge Dinis-Oliveira ^1,6,9,10, Hassan Bousbaa ⁴ and Sara Ricardo ^1,2,3,4,

¹ Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal.

Investigadores do Instituto Universitário de Ciências da Saúde – CESPU e da Unidade de Biociências Moleculares Aplicadas (UCIBIO) em colaboração com investigadores do Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S) e Instituto de Investigação em Ciências da Vida e da Saúde (ICVS) descobriram que a metformina reduz o efeito anti-tumoral do linsitinib no contexto do cancro de ovário.

Venous thromboembolism (VTE) affects up to 20% of cancer patients, presenting a risk four to seven times higher than that of the general population. This elevated risk is attributed to factors related to the patient, the tumour, and treatments. When deciding on primary thromboprophylaxis, these factors, along with the potential for bleeding and the impact on the patient’s quality of life, are considered.

O tromboembolismo venoso (TEV) afeta até 20% dos doentes com cancro, apresentando um risco quatro a sete vezes superior ao da população geral. Este risco elevado é atribuído a fatores relacionados com o paciente, tumor e tratamentos. Na decisão sobre a tromboprofilaxia primária, estes fatores, juntamente com o potencial para hemorragia e impacto na qualidade de vida do paciente, são considerados.

Sint Michielsgestel, Netherlands

14 - 20 June, 2024

See more informations here: https://event.eortc.org/mccr2025/

Sint Michielsgestel, Netherlands

14 - 20 June, 2024

See more informations here: https://event.eortc.org/mccr2025/

Brussels & online

20-21 November, 2024

See more informations here: https://www.europeancancer.org/summit.html

Researchers from the "Differentiation and Cancer" group at i3S, in collaboration with António Pombinho, from the "BioSciences Screening" platform, and Filipe Pereira, from Lund University, elucidated the role of the transcription factor HMGA1 in gastric cancer stem cells. The study, entitled "HMGA1 stimulates cancer stem-like features and sensitivity to monensin in gastric cancer," was recently published in the journal "Experimental Cell Research."